Research programme: quinoline compounds - Active Biotech

Drug Profile

Research programme: quinoline compounds - Active Biotech

Alternative Names: Inhibition of S100A9 Interactions; ISI; S100A9 Inhibition by Low molecular weight Compounds; SILC

Latest Information Update: 17 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Active Biotech
  • Class Quinolines
  • Mechanism of Action Advanced glycosylation end-product receptor antagonists; Toll-like receptor 4 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Cancer

Most Recent Events

  • 16 Apr 2018 Research programme: quinoline compounds - Active Biotech is available for licensing as of 16 Apr 2018. www.activebiotech.com
  • 15 Jan 2018 Active Biotech receives patent allowance for quinoline compounds in USA
  • 16 Feb 2017 Active Biotech has patent protection for quinoline compounds in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top